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H5N1 avian influenza viruses remain a threat to public health
mainly because they can cause severe infections in humans. These
viruses are widespread in birds, and they vary in antigenicity form-
ing three major clades and numerous antigenic variants. The most
important features of the human monoclonal antibody FLD194
studied here are its broad specificity for all major clades of H5
influenza HAs, its high affinity, and its ability to block virus in-
fection, in vitro and in vivo. As a consequence, this antibody may
be suitable for anti-H5 therapy and as a component of stockpiles,
together with other antiviral agents, for health authorities to use if
an appropriate vaccine was not available. Our mutation and struc-
tural analyses indicate that the antibody recognizes a relatively con-
served site near the membrane distal tip of HA, near to, but distinct
from, the receptor-binding site. Our analyses also suggest that the
mechanism of infectivity neutralization involves prevention of re-
ceptor recognition as a result of steric hindrance by the Fc part of
the antibody. Structural analyses by EM indicate that three Fab frag-
ments are bound to each HA trimer. The structure revealed by X-ray
crystallography is of an HA monomer bound by one Fab. The mono-
mer has some similarities to HA in the fusion pH conformation, and
the monomer’s formation, which results from the presence of isopro-
panol in the crystallization solvent, contributes to considerations of
the process of change in conformation required for membrane fusion.
influenza virus | neutralizing antibody | H5N1
The initial steps in influenza virus infection involve sialic acidreceptor binding and membrane fusion, both of which are
functions of the hemagglutinin (HA) virus membrane glycopro-
tein. Anti-HA antibodies that block these functions neutralize
virus infectivity. Such antibodies are induced by infection and by
vaccination, and the immune pressure that they impose on sub-
sequently infecting viruses is responsible for the antigenic drift
for which influenza viruses are notorious. Zoonotic infections,
which can lead to new pandemics, occur periodically, and H5N1,
H7N9, and H10N8 avian viruses are recent examples of this sort.
The threat that zoonotic infections present is based, in part, on
the lack of immunity in the human population to the novel HAs
that they contain. In attempts to substitute for this deficiency,
human immune sera have been used successfully to treat severe
infections (1), and monoclonal antibodies have been prepared
from mice and from humans for potential use in immunotherapy.
Analyses of antibodies produced by cloned immune cells derived
from infected patients have revealed that antibodies are induced
that are either subtype- or group-specific and others that cross-react
with HAs of both groups (2). To date, cross-reactive antibodies
have been shown to recognize both membrane-distal and mem-
brane-proximal regions of HA (3). Subtype-specific antibodies, on
the other hand, bind to the membrane-distal region, covering the
receptor-binding site and, in some cases, inserting into it (4, 5).
In the studies reported here, a human monoclonal antibody is
described that recognizes the HAs of viruses of all three clades of
the H5 subtype that have caused human infection and is shown
to be effective in protecting mice from lethal challenge. EM and
X-ray crystallography studies of HA-Fab complexes indicate that
the antibody binds to a site containing residue 122, located on the
membrane-distal surface of the HA trimer. We describe the an-
tibody-binding site in detail to show that binding occurs at a dis-
tance from the receptor-binding site. Infectivity neutralization
and receptor-binding experiments, together with these observa-
tions, lead to the conclusion that the antibody neutralizes viruses
by blocking receptor binding in a way that is dependent on the Fc
region of the bound antibody. We compare the site with similar
sites reported by others (6–9) for antibodies that have not as yet
given crystalline HA-Fab complexes.
Under the conditions that we obtain crystals of the HA-Fab
complex, the HA dissociates and reveals the structure of a mono-
meric HA. We consider the structure of the monomer in relation to
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the structure that HA has been shown to assume after exposure
to the pH of membrane fusion.
FLD194 Neutralizes Infectivity of a Broad Range of H5N1
Viruses, in Vitro and in Vivo
Blood samples from a Vietnamese adult (donor CL115) who had
recovered from infection with a clade 1 H5N1 virus, were collected
15 mo after infection (10). IgG-memory B cells were immor-
talized with EBV (11). Cultures secreting neutralizing anti-
bodies were identified by a microneutralization assay using the
prototype H5N1 clade 1 virus, A/Vietnam/1203/04, and the
antibodies were cloned by limiting dilution. Two H5N1-neu-
tralizing antibodies were identified, FLD84 and FLD194. We
have studied the latter in more detail.
The cross-reactivity of FLD194 was determined in neutraliza-
tion assays using a panel of 13 human and avian pseudotype H5N1
viruses representative of clades 0, 1, 2.1.3, 2.2, 2.2.1, 2.3.1, 2.3.2,
2.3.2.1, 2.3.4, and 2.5. The IgG was found to be highly effective
against all of the viruses tested. By comparison, two other anti-H5
antibodies, FLD20 [previously obtained from the same individual
(10)] and FLD84, had lower potency and did not neutralize all of
the strains (Table 1).
To determine whether the in vitro neutralizing activities of the
human monoclonal antibodies would correlate with their pro-
phylactic efficacy, BALB/c mice were inoculated i.p. with either
25 or 2.5 mg/kg of FLD194 or a control monoclonal antibody and
were challenged 24 h later with 10 MLD50 (50% mouse lethal
doses) of A/Vietnam/1203/04 (H5N1, clade 1) (Fig. 1 A and C) or
A/Indonesia/5/05 (H5N1, clade 2) (Fig. 1 B and D). FLD194 at
either concentration protected mice from lethal challenge with
either H5N1 virus. To gain further insights into the kinetics of virus
neutralization in vivo by FLD194, we measured the level of viral
replication in nasal turbinates, the lungs, and the brains on days 2
and 4 post infection. The antibody significantly reduced virus titers
in the nasal turbinates and lungs of mice infected with either H5N1
strain (Fig. 1 E and F) and restricted extrapulmonary dissemination
of the virus. Prophylactic administration of FLD194 IgG (and
FLD84) at 7.5 mg/kg also protected ferrets against lethal challenge
from the clade 1 A/Vietnam/1203/04 virus (SI Appendix, Fig. 1).
Structure of the FLD194 HA-Fab Complex
To characterize the interaction of the antibody with H5 HA, we
measured binding of the Fab to insect cell-expressed H5 HA
from the aerosol-transmissible mutant clade 1 virus (12, 13) by
isothermal titration calorimetry. The binding is exothermic, with
a KD of 36 nM and a stoichiometry close to 3 (SI Appendix, Fig.
2), suggesting that one Fab would bind to each subunit in an HA
trimer. EM images of purified HA-Fab complexes also show a
clear threefold symmetry indicating that three Fab fragments
bind to each HA trimer.
To define the epitope of FLD194 in atomic detail, we crys-
tallized the HA-Fab complexes from the preparation used for
Fig. 1. Antibody FLD194 protects BALB/c mice from
challenge with H5N1 viruses. Mice received 2.5 or
25 mg/kg FLD194 or an irrelevant antibody as control,
intraperitoneally 24 h before infection with 10 MLD50
of either A/Vietnam/1203/2004 (H5N1) (A and C) or
A/Indonesia/5/2005 (H5N1) (B and D). Survival (A and B)
and body weight (C and D) were recorded daily. The
distribution of virus in different tissues following in-
fection with 105 TCID50 (tissue culture infectious dose)
of either A/Vietnam/1203/2004 (H5N1) or A/Indonesia/
5/2005 (H5N1) is shown in E and F. Dotted lines in-
dicate the limit of virus detection.
Table 1. Neutralization breadth of a panel of monoclonal
antibodies against pseudotype viruses containing a diverse
set of H5 HAs
Virus origin of HAs Clade
IC90, μg/mL
FLD20 FLD84 FLD194
A/Hong Kong/156/97 0 0.003 0.005 0.008
A/Hong Kong/213/03 1 0.033 0.117 0.007
A/Vietnam/1203/04 1 0.600 0.240 0.023
A/Vietnam/1194/04 1 0.144 0.357 0.019
A/Indonesia/05/05 2.1.3 0.149 0.280 0.033
A/whooper
Swan/Mongolia/244/05
2.2 0.345 0.293 0.008
A/bar-headed
goose/Qinghai/1A/05
2.2 0.010 0.015 0.036
A/Egypt/3300-NAMRU3/08 2.2.1 >20 >20 0.020
A/turkey/Turkey/1/05 2.2.1 0.355 0.117 0.019
A/common magpie/HK/5052/07 2.3.2 >20 >20 0.046
A/Hubei/01/10 2.3.2.1 >20 >20 0.013
A/Anhui/1/05 2.3.4 0.607 0.195 0.131
A/chicken/Korea/ES/03 2.5 0.010 0.018 0.042
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EM and determined their structures by X-ray crystallography.
Unlike the EM observations, the crystalline HA-Fab complex
consists of a 1:1 complex of the Fab with monomeric HA (Fig. 2A)
instead of the 3:3 trimeric complex. Because the H5 HA crystallizes
at pH 7.5 as trimers (12), it is likely that the inclusion of isopropanol
in the solvent on this occasion led to dissociation of the HA trimer
and promoted crystallization. The known ability of isopropanol to
enhance the formation of α-helices by proteins that are in a helix-
coil equilibrium (14) is consistent with a role in the formation of the
HA monomer. Gel-filtration analyses indicate that about 50% of
the H5 aerosol-transmissible mutant HA dissociates into smaller
species on incubation for 8 h in 20% isopropanol.
Structural alignment of the receptor-binding domain (RBD)
of the HA-Fab complex with that of the trimeric structure of the
H5 HA (12) gives an rmsd of 0.39 Å (Fig. 2C), indicating that the
structure of the RBD is almost unchanged in the crystalline
monomer. Consistent with this, it is possible to dock three FLD194
Fabs onto an HA trimer using the monomeric RBD of the HA-Fab
complex as a guide (Fig. 3B). Viewed down the HA threefold
axis, it is evident that the Fab binds to the membrane distal
domain of HA between the 140-loop and the carbohydrate side-
chain attached to residue 169 (Fig. 3B). The Fab heavy chain
(green) covers the “140 side” of this region, and the Fab light
chain (orange) contacts the “169 side.”
The Fab contacts the HA surface using five of the six com-
plementarity determining regions (CDRs) (Fig. 4A). The contact
area spans multiple antigenic sites previously defined using
mouse monoclonal antibody-selected antigenic variants of H1
and natural antigenic variants of H3 HAs (15, 16) (Fig. 4B).
Heavy chain CDR1 (HCDR1) contacts the 140-loop, site
A (Ca2), and HCDR2 contacts residues near residue 81, site
E (Cb). HCDR3 contacts a region between residues Gln-122 and
Ser-126, sites E (Cb) and B (Sa), respectively. Two light chain
CDRs (LCDRs) make contacts near residue 128, at site B (Sa),
and LCDR1 also contacts residue 122 in site E (Cb). Binding of
the CDRs accounts for a buried surface area of 777 Å2 on HA.
Based on the structure, the major part of the epitope recognized
by FLD194 consists of residues 120–128 that form the center of
the antibody-binding site (SI Appendix, Fig. 3). This part of the site
has a surface area of 439 Å2, comprising 56% of the total buried
surface area of HA. At the epitope’s C terminus, it adopts a short
helical structure containing residue 125B, the second of two
inserted residues that are specific features of group 1 HAs at this
position. Three residues, Gln-122, Pro-125, and the Ser-125B are
contacted by both heavy and light chains (colored purple in Fig. 4
A and C; also see SI Appendix, Fig. 3). Of the three contacted
residues, binding to Gln-122 contributes the largest buried surface
area of 89 Å2. This is consistent with the observations that the
Gln-122Arg substitution in H5 HA severely restricts the neutral-
ization activity of FLD194 and that the only viruses tested that
were not neutralized had arginine or lysine at residue 122 (SI
Appendix, Table 1 and Fig. 4) A bioinformatics analysis using H5
sequences from GISAID and NCBI databases (SI Appendix, Figs.
5 and 6) revealed that residue 122 is highly conserved, 99%, as
glutamine in human isolates, including those obtained recently
Fig. 3. Solution structure of the FLD194 HA-Fab
complex. (A) Negative stain EM of FLD194 Fab-H5
transmissible mutant HA complex. Most particles
exhibit threefold symmetry (Top); selected particles
are magnified (Middle) and depicted with schematic
drawings (Bottom). (B) Models of a transmissible
mutant HA trimer on which three FLD194 Fabs are
docked, based on a combination of crystallographic
(Fig. 2A) and EM (A) data. A view from the side and a
view down the threefold axis of symmetry are shown.
Fig. 2. Crystal structure of the FLD194 HA-Fab
complex. (A) Cartoon representation of the struc-
ture of the Fab-H5–transmissible mutant HA com-
plex showing HA1 (blue) and HA2 (red), and the
heavy (green) and light (orange) chains of the an-
tibody. The HA in the complex is a monomer, and
helix-A in HA2 is extended by refolding of the
interhelical loop. (B) HA monomer taken from the
native HA trimer for comparison with A. (C) An
alignment of the HA structures in A and B obtained
by superpositioning of the RBDs of HA1. (D) An
alignment of the HA structures in A and B obtained
by superpositioning of the helices B of HA2 shows that
there is a slight reorientation of RBD in the HA-Fab
complex structure comparing to that in the structure
of a trimeric HA subunit.










from Egypt and Cambodia, and less conserved, 91%, in avian
H5 isolates.
FLD194 binding involves extensive interactions between
HCDR3 and the 140-loop side of the epitope (Fig. 4C) and LCDR1
to the side containing residue 169. Together, they form a clamp
around the 120–128 strand. The extended HCDR3 loop may be
stabilized by a disulfide bond between Cys-98 and Cys-100C (Fig.
4 C and D) in a similar way to what has been observed in the
HCDR3 of an anti-HIV envelope glycoprotein antibody where
the disulfide was proposed to fix the CDR loop in a particular
conformation for epitope recognition (17). The Cys-98 side of
HCDR3 penetrates the cleft between the 140-loop and the 120–
128 strand of HA, and this penetration allows Ser-99 of HCDR3
to form hydrogen bonds with residues located in the cleft, in-
cluding Lys-120 in the 120–128 strand of HA and Tyr-256 and
Asn-81 of adjacent structures (Fig. 4D). The Cys-100C side of
HCDR3 covers the 120–128 strand, and both Ser-100B and
Tyr-100D form hydrogen bonds with Gln-122. On the Asn-169 side
of the site (Fig. 4E), Asn-28 and Tyr-30 of LCDR1 form hydrogen
bonds with Ile-123 and Ser-126, respectively, and Tyr-32 covers
Gln-122. These interactions are also stabilized by hydrogen bonds
between Asn-28 and Asn-169.
Comparison with Similar Anti-H5 HA Human Monoclonal
Antibodies
The binding sites of several other human monoclonal antibodies
have been reported to be located at similar surface areas of HA
to those recognized by FLD194. These antibodies have not been
characterized by X-ray crystallography, but the epitopes recog-
nized by them have been identified using different mapping
techniques. Most of the antibodies bind to the 120–128 strand (SI
Appendix, Fig. 7), and FLA5, FLD21 (6) (SI Appendix, Fig. 7B),
AVFluIgG01, AVFluIgG03 (7) (SI Appendix, Fig. 7C), and C65C6
(8) (SI Appendix, Fig. 7SD) select escape mutants containing HA
amino acid substitutions near Pro-125 (SI Appendix, Fig. 7D). The
Fig. 4. Binding site of the FLD194 antibody. (A) Footprint of FLD194 on the H5-transmissible mutant HA surface. Areas contacted by heavy, light, and both
chains of the FLD194 Fab fragment are colored green, orange, and purple, respectively. Heavy and light chain CDRs are shown and colored white. The receptor-
binding site is indicated by a modeled receptor in red dashed bonds. (B) Surface representation of H5-transmissible mutant HA with previously identified
antigenic sites of group 1 HA (16). (C) Cartoon representation of H5-transmissible mutant HA and bound FLD194 CDR loops; interactions made by HCDR3 and
LCDR1 are shown in detail in D and E, with slightly reoriented views. Blue and red dots indicate backbone amide and carbonyl groups, respectively.
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escape mutant selected by the antibody 100F4 (9) was also mapped
to Glu-225, a residue that is contacted by the HCDR3 of FLD194.
FLD194 Antibody Blocks Receptor Binding and Neutralizes
Virus by Its Fc Region
A common mechanism of neutralization by strain-specific anti-
influenza antibodies involves inhibition of receptor binding (18).
The crystal structure of the complex formed by the FLD194 Fab
with H5 HA shows that the receptor-binding site is not contacted
by the antibody (Fig. 4). Nevertheless, the antibody is highly
effective in neutralizing H5 viruses (IC90∼100 ng/mL) by com-
parison with HA2-reactive antibodies, such as FI6, which has
very little receptor blocking activity (IC90, >1,000 ng/mL) (2).
To investigate the mechanism of infectivity neutralization by
FLD194 IgG, we tested its ability to block receptor binding by
H5N1 virus using biolayer interferometry (SI Appendix, Fig. 8).
The results show that at receptor analog loading levels that allow
the virus to saturate the biolayer, a concentration of ∼150 nM
FLD194 IgG is needed to block avian receptor binding by 100 pM
wild-type H5 virus (SI Appendix, Fig. 8). Wild-type H5 virus
binding to human receptor is weak, and comparable data could
not be obtained. However, similar concentrations of FLD194
IgG are required to block binding of 100 pM of a mutant H5
virus that has measurable affinity for both avian and human re-
ceptors (19) (SI Appendix, Fig. 8). FLD194, therefore, inhibits
both avian and human receptor binding. Given that there are
∼300–500 HA trimers per virus (i.e., 90–150 nM binding sites for
100 pM virus), the receptor-binding inhibition data suggest
complete receptor-binding inhibition requires stoichiometric
binding to each HA subunit. Under conditions where inhibition
of receptor binding by FLD194 is incomplete, it is possible that
neutralization at lower antibody occupancy could occur at the
membrane fusion stage of virus entry as a consequence of HA
cross-linking by antibody, as observed in Fig. 5.
When similar receptor-binding inhibition experiments were
done using the FLD194 Fab fragment instead of FLD194 IgG,
inhibitory activity was greatly reduced (SI Appendix, Fig. 8 B and
D) and receptor binding was not fully blocked by up to 1500 nM
Fab, which represents a reduction in receptor-binding inhibi-
tion by at least a factor of 100. The importance of the Fc re-
gion for the neutralizing activity of FLD194 is also indicated
by the fact that FLD194 Fab does not neutralize virus even up to
0.1 mg/mL, representing a reduction of neutralization activity of
at least 1,000-fold.
To understand how the Fc region of FLD194 blocks receptor
binding and facilitates virus neutralization, we examined how
FLD194 IgG binds to influenza virus and to HA-rosettes by EM
(Fig. 5). The micrograph of H5 HA-rosette-IgG complexes in-
dicates that FLD194 binds between two neighboring HAs and
cross-links them (Fig. 5A). The orientation of the Fab fragment
of IgG bound to HA is similar to that observed for Fab in the
crystal structure of the HA-Fab complex. When FLD194 IgG
binds to the virus, it forms a layer about 80 Å thick above the
HA-decorated virus surface (Fig. 5 B and C). Because the Fab
binds to HA almost horizontally, with a binding angle of about
100°, the thickness of the IgG layer can be attributed primarily to
the projecting Fc regions of the bound antibodies. Together with
our receptor blocking and infectivity neutralization data, it can
also be concluded that this layer restricts the access of the virus
to cell-surface sialic acid receptors, sterically preventing virus
attachment. Bound Fab fragments would be much less effective
inhibitors of attachment. These conclusions are similar to those
made before for an infectivity neutralizing mouse monoclonal
antibody, which binds outside the receptor-binding site. Removal
of the Fc in that case also resulted in a 3-log reduction in neu-
tralizing activity, and a similar conclusion was drawn that neu-
tralization by the antibodies is a result of the Fc regions shielding
virus HA from cellular receptors (20). In some infections and
under lower effective concentrations of antibody, it is possible
that virus–antibody complexes could enhance infection through
cellular uptake following interaction with Fc receptors (21).This
possibility should be explored before use of this or other anti-
bodies as antiviral treatments is recommended.
Structure of HA in the FLD194 Fab-H5 HA Complex
Each subunit of the native HA trimer contains two polypeptides,
HA1 and HA2. HA2 contains two prominent α-helices, helix-A
and helix-B, with the longer helix-B forming a coiled-coil through
interactions with helix-B in HA2 of the other subunits in the tri-
mer (Fig. 2B). In an HA trimer, the C terminus of helix-A is linked
to the N terminus of helix-B by an extended interhelical loop,
HA2 residues 58–75 (Fig. 2B). In the HA structure found in the
FLD194 Fab-H5 HA complex, both HA1 and HA2 are compo-
nents of a monomer, interactions made between HA1 and the
extended interhelical loop are lost, and helix-A is extended by five
turns to form a continuous α-helix from residue 38–75 (Fig. 2A).
Before the HA structure was determined by X-ray crystallog-
raphy (22), HA2 residues 38–75 were predicted to have the pro-
pensity to form an α-helix (23), and this prediction was confirmed
using synthetic peptides (24). Subsequently, comparison of the
structures of HA in the neutral pH and the fusion pH conforma-
tions showed directly that helix-A, the interhelical-loop, and the
N-terminal residues of helix-B (residues 76–105) form continuous
α-helices in a trimeric coiled-coil at fusion pH (25). The extended
helix-A observed here in the monomeric HA structure is, there-
fore, a component of the postfusion HA structure (Fig. 2A; also
compare Fig. 2 A and B). This structure’s formation occurs as part
of the process of trimer dissociation; the extension of helix-A itself
may be responsible for trimer dissociation, or it may occur on
dissociation and, once formed, it may prevent trimer reformation.
By contrast, retention of the coiled-coil structure formed at the N
terminus of helix-B in both neutral pH- and fusion pH-HA struc-
tures, has been taken to suggest that complete dissociation of the
trimer and trimer reformation are not components of the structural
transition required for membrane fusion (25). The observations
here, however, may give support to the alternative possibility.
In relation to the structural changes required for membrane
fusion, two other features of the monomer in the FLD194 HA-Fab
complex can be considered. Firstly, the observation that the
Fig. 5. Electron micrographs of FLD194 IgG bound to HA rosettes and virus.
(A) Image of A/Vietnam/1194/2003 H5 HA rosettes in complex with FLD194
IgG (Upper); cartoon representations of the micrographs are shown (Lower).
(B) A/Vietnam/1194 (RG14) H5N1 virus with a few IgG bound showing an
ordered layer of HA on the virus surface. (C) A/Vietnam/1194 (RG14) H5N1
virus bound with FLD194 IgG. The bound antibody molecules form an extra
layer above the HA molecules on the virus surface; the white arrows indicate
examples of an IgG cross-linking two HAs.










structure of the monomeric membrane distal domain, HA1, is
highly similar to that in a subunit of the trimer (Fig. 2C) indicates
that complete trimer dissociation can occur without denaturation
of this domain. A similar observation was made for the structure of
the monomeric membrane distal domain following its dissociation
at fusion pH (26). Secondly, refolding of the interhelical loop re-
sults in loss of all of the interactions between the loop and HA1.
As a consequence HA1 is less tightly packed against HA2 as well
as being dissociated into monomers (Fig. 2D). The “fusion pep-
tide,” by contrast, is retained in its neutral pH position, implying
that neither dissociation nor partial HA1 detachment directly re-
sults in the fusion peptide’s extrusion.
Conclusion
We have characterized the structure, virus binding, and in-
fectivity-neutralizing specificity of a human monoclonal antibody
derived from an H5N1-infected survivor. The antibody is char-
acterized by high infectivity-neutralizing potency and a broad
spectrum neutralizing activity against human and avian H5N1
viruses in vivo and in vitro. Our structural analysis of the Fab
complex with H5 HA reveals that the Fab binds outside the
receptor-binding site to a relatively conserved epitope. EM anal-
yses of IgG-HA and IgG-virus complexes, together with receptor
inhibition and virus-neutralization assays, suggest that FLD194
neutralizes viruses by blocking receptor binding, shielding HAs
from cellular receptors by the Fc parts of the antibody. The lo-
cation of the epitope and the suggested role of antibodies bound
to it are consistent with conclusions that antigenic variation can
result from amino acid substitutions distributed over the whole
membrane distal surface of HA and distant from the receptor-
binding site. The relative sizes of the membrane distal domain
and an antibody are consistent with a major role in infectivity
neutralization of receptor-binding inhibition by the Fc regions
of antibodies that bind in these locations. In the course of
crystallization of the HA-Fab complex, we obtained a mono-
meric form of HA. A similar structure was reported before for
H1 HA, which, by contrast, contained a reoriented HA1 and a
disordered HA2 interhelical loop (27). In the monomeric HA
described here, the interhelical loop refolds into an α-helix that
extends helix-A in HA2, in a manner reminiscent of the structure
that HA2 adopts at fusion pH.
Materials and Methods
Human monoclonal antibodies were isolated from cloned B cells, and their
neutralization activities and in vivo efficacies were assessed as previously
described. LysC-digested Fab fragments were incubated with transmissible
H5 HA, and the complexes formed were purified from unbound Fab by gel-
filtration. Purified complexes were examined by negative stain EM. Crystals
of the Fab-H5 HA complex were obtained by sitting drop vapor diffusion
and analyzed by cryocrystallography. The Fab-H5 HA structure was determined
by molecular replacement. The atomic structure coordinates and structure
factors have been deposited in the Protein Data Bank as PDB ID code 5A3I.
Receptor-blocking activity was measured by biolayer interferometry using an
Octet RED instrument (ForteBio) by immobilizing polymeric receptor analogs
on streptavidin biosensors to which influenza virus binding was monitored in
the absence or presence of varying concentrations of IgG or Fab. Additional
detailed information is described in SI Appendix, Materials and Methods.
All experiments involving highly pathogenic avian influenza viruses were
conducted in a Biosafety Level 3 (BSL3) containment facility that was ap-
proved for use by the US Department of Agriculture and Centers for Disease
Control and Prevention. Animal experiments were approved by the National
Institutes of Health Animal Care and Use Committee.
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